Related Experiment Video
Updated: Aug 18, 2026

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
Published on: July 9, 2016
M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders
Katerina Zavitsanou1, Andrew Katsifis, Yinghua Yu
1Radiopharmaceuticals R&D, Australian Nuclear Science and Technology Organisation (ANSTO), PMB 1, Menai, Sydney, NSW 2234, Australia. kza@ansto.gov.au
Abstract:
We have previously shown a decrease in [(3)H]pirenzepine binding to M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia but not in major depression or bipolar disorder. The present study aimed to extend these findings by examining the binding of [(3)H]AF-DX 384 to M2/M4 receptors in the same cohort of subjects. Using quantitative autoradiography we measured [(3)H]AF-DX 384 binding in the anterior cingulate cortex of 15 schizophrenia, 15 bipolar, 15 major depression and 15 control cases. Post-mortem tissue was obtained from the Stanley Foundation Brain Bank. [(3)H]AF-DX 384 binding had a homogenous distribution amongst the layers of the anterior cingulate cortex, was higher in males than in females and declined with prolonged storage of tissue. An inverse correlation between [(3)H]AF-DX384 binding and age of onset of the disease was observed in the schizophrenia group suggesting that the earlier the age at onset the higher the binding was. In the depression group, there was a significant effect of gender on [(3)H]AF-DX 384 binding with females having lower binding in comparison to males. In the bipolar group, there was a significant inverse correlation between antipsychotic medication and [(3)H]AF-DX 384 binding, suggesting that the higher the dose of medication the lower the binding was. No differences in [(3)H]AF-DX 384 binding were seen between the four groups. The present results provide no evidence of M2/M4 receptor alterations in the anterior cingulate cortex in schizophrenia and affective disorders and extend the body of evidence implicating cortical M1 but not M2 involvement in the pathology and pharmacotherapy of schizophrenia.
Insights
This study found no changes in M2/M4 muscarinic receptors in the anterior cingulate cortex of individuals with schizophrenia, major depression, or bipolar disorder. Previous research implicated M1 receptors in schizophrenia, suggesting M1, not M2, involvement.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Previous studies indicated reduced M1/M4 muscarinic receptor binding in the anterior cingulate cortex (ACC) in schizophrenia.
- This reduction was not observed in major depression or bipolar disorder.
Purpose of the Study:
- To investigate M2/M4 muscarinic receptor binding in the ACC using [(3)H]AF-DX 384.
- To examine these receptors in patients with schizophrenia, bipolar disorder, and major depression.
Main Methods:
- Quantitative autoradiography was employed to measure [(3)H]AF-DX 384 binding in post-mortem ACC tissue.
- The study included 15 cases each of schizophrenia, bipolar disorder, major depression, and controls.
Main Results:
- No significant differences in [(3)H]AF-DX 384 binding were found between the four diagnostic groups.
- Binding was higher in males than females and decreased with tissue storage time.
- In schizophrenia, earlier age of onset correlated with higher binding; in depression, females had lower binding than males.
Conclusions:
- The findings do not support alterations in M2/M4 receptors in the ACC in schizophrenia or affective disorders.
- This reinforces the hypothesis of cortical M1 receptor involvement in schizophrenia pathology and treatment, rather than M2 receptors.
More Related Videos
05:14Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
07:25Identification of Dopamine D1-Alpha Receptor Within Rodent Nucleus Accumbens by an Innovative RNA In Situ Detection Technology
Published on: March 27, 2018
Related Concept Videos
Cholinergic Receptors: Muscarinic
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Cholinergic Antagonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Pharmacological Actions